Search

Olcegepant

Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine. … Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks

TJ003234

Taribavirin

OSI-461

OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).

Isoflurane

A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.

Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen

Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is a vaccine for intramuscular injection used in the prevention of invasive disease caused by *Haemophilus … vaccine contains the *Haemophilus influenzae* type b capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP), a high-molecular-weight polymer prepared from the *H. influenzae* type b strain 1482 grown in

NCX 701

Nitroparacetamol (NCX-701) is a newly synthesized nitric oxide-releasing derivative of paracetamol.

Human Embryonic Stem Cell-derived M Cell

IMRCs are similar to MSCs in terms of their capacity for self-renewal and tri-lineage differentiation. … However, the difference comes with IMRCs displaying a higher quality of consistency, having stronger immunomodulatory and anti-fibrotic functions, and being stronger in potential treatment of lung injury

R673

The phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning

Darapladib